Evidence map›Paper›PMID 32280091›Full record

SynthesisJournal of Alzheimer's disease : JAD2020

Use of Immersive Virtual Reality in the Assessment and Treatment of Alzheimer's Disease: A Systematic Review.

Felix Clay, David Howett, James FitzGerald, Paul Fletcher, Dennis Chan, Annabel Price

Registry-linked trialOpen access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05265182 (Developing an Immersive Gamification Technology System), which is not on this map. Cited by 47 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 5 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05265182 nacompletednot on this mapstarted 2022, after this paper: background citation

Developing an Immersive Gamification Technology System (ImGTS) for the Management of Patients With Behavioral and Psychological Symptoms of Dementia (Phase 1 Trial)

TypeinterventionalSponsorAugmented eXperience E-health LaboratoryRan2022 to 2022Enrolled30ConditionsDementia AlzheimersArmsvirtual reality
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 5 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Clinical Therapy in Dementia and Related Diseases.Journal of clinical medicine · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Advances in laboratory medicine · 2024
    Article
  15. Article
  16. Applications of the metaverse in medicine and healthcare.Advances in laboratory medicine · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Felix ClayCambridge and Peterborough Foundation Trust, Elizabeth House, Fulbourn Hospital Cambridge, Cambridge, UK.
David HowettUniversity of Cambridge, Department of Clinical Neurosciences, Cambridge Biomedical Campus, Cambridge, UK.
James FitzGeraldCambridge and Peterborough Foundation Trust, Elizabeth House, Fulbourn Hospital Cambridge, Cambridge, UK.
Paul FletcherCambridge and Peterborough Foundation Trust, Elizabeth House, Fulbourn Hospital Cambridge, Cambridge, UK.
Dennis ChanUniversity of Cambridge, Department of Clinical Neurosciences, Cambridge Biomedical Campus, Cambridge, UK.
Annabel PriceCambridge and Peterborough Foundation Trust, Elizabeth House, Fulbourn Hospital Cambridge, Cambridge, UK.
Fulbourn Hospital · GBUniversity of Cambridge · GBUniversity College London · GB

Funding

Department of Health
6 · The paper itself

Abstract

backgroundImmersive virtual reality (iVR) allows seamless interaction with simulated environments and is becoming an established tool in clinical research. It is unclear whether iVR is acceptable to people with Alzheimer's disease (AD) dementia or useful in their care. We explore whether iVR is a viable research tool that may aid the detection and treatment of AD.

objectivesThis review examines the use of iVR in people with AD or mild cognitive impairment (MCI).

methodsMedline, PsycINFO, Embase, CINAHL, and Web of Science databases were searched from inception. PRISMA guidelines were used with studies selected by at least two researchers.

resultsNine studies were eligible for inclusion. None reported any issues with iVR tolerability in participants with MCI and AD on assessment or treatment tasks. One study demonstrated capability for detecting prodromal AD and correlated with neuroanatomical substrates. Two studies showed iVR to have high accuracy in differentiating participants with AD from controls but were not hypothesis driven or with adequate controls measures. In a small validation study and two longitudinal case studies, iVR cognitive training was positively rated but did not demonstrate reliable benefit.

conclusioniVR is emerging as a viable method of assessing older adults and people with AD. Strongest benefits were seen when closely integrated with theoretical models of neurodegeneration and existing screening methods. Further randomized controlled trials integrated with clinical populations are required. This will consolidate the power of iVR for assessment of MCI and clarify treatment efficacy beyond current applications in physical rehabilitation.

Indexed as

Virtual RealityAlzheimer DiseaseCognitive DysfunctionCognitive RemediationDisease ProgressionHumansSpatial NavigationAlzheimer’s diseasecognitive remediationmild cognitive impairmentspatial navigationvirtual reality

Identifiers

PMID32280091
PMCPMC7306888
OpenAlexW3015300153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.